Synergistic nutritional compositions for treating vestibular associated neurodegenerative diseases
The invention disclosed herein relates to synergistic nutritional compositions for treating vestibular associated neurodegenerative diseases. Particularly, the invention relates to synergistic nutritional compositions comprising an exogenous blend of N-acetyl-DL-leucine (NADLL) enantiomerically enriched with L-leucine and uridine monophosphate (UMP) which are present in a weight ratio of 1:0.002 to 1:0.8 along with pharmaceutically acceptable excipients. The composition of the present invention is useful for treating dizziness, imbalance, vertigo, tinnitus, hearing loss, brain fog, vision impairment, cognitive changes, Alzheimer's disease, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), motor neurone disease (MND), multiple system atrophy (MSA), and Parkinson's disease (PD).
1 . A synergistic composition for treating vestibular associated neurodegenerative diseases, the composition comprising: an exogenous blend of N-acetyl-DL-leucine enriched with L-leucine and uridine monophosphate, wherein the exogenous blend comprises N-acetyl-DL-leucine enriched with L-leucine and uridine monophosphate, and wherein a weight ratio of N-acetyl-DL-leucine enriched with L-leucine to uridine monophosphate is in a range of 1:0.002 to 1:0.8.
2 . The synergistic composition as claimed in claim 1 , wherein the N-acetyl-DL-leucine enriched with the L-leucine is present in a range of 50% to 98% by weight of the total composition.
3 . The synergistic composition as claimed in claim 1 , wherein the uridine monophosphate is present in a range of 0.1% to 35% by weight of the total composition.
4 . The synergistic composition as claimed in claim 1 , wherein the N-acetyl-DL-leucine comprises D-leucine in a range of 5% to 45% and the L-leucine in a range of 55% to 95% by weight of the total N-acetyl-DL-leucine.
5 . The synergistic composition as claimed in claim 1 , wherein the N-acetyl-DL-leucine enriched with the L-leucine and the uridine monophosphate are present in a white crystalline form.
6 . The synergistic composition as claimed in claim 1 , wherein the pharmaceutically acceptable excipients are selected from a group consisting of a diluent present in a range of 1 to 30%; a binder present in a range of 0.1 to 25%; a lubricant present in a range of 0.1 to 10.0%; a glidant present in a range of 0.1 to 5.0%; an additive present in a range of 1 to 10%; a surfactant present in a range of 0.1 to 5.0%; a stabilizer present in a range of 0.1 to 5.0%, an antioxidant present in a range of 0.1 to 5.0%; and a plasticizer present in a range of 0.1 to 5.0%, by weight of the total composition.
7 . The synergistic composition as claimed in claim 1 , wherein the vestibular associated neurodegenerative diseases are selected from a group consisting of dizziness, imbalance, vertigo, tinnitus, hearing loss, brain fog, vision impairment, cognitive changes, Alzheimer's disease, progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), motor neurone disease (MND), multiple system atrophy (MSA), and Parkinson's disease (PD).